Market Access News | pharmaphorum

News

Sandoz files biosimilar of Amgen osteoporosis drug in US

Novartis' soon-to-be-divested Sandoz unit has filed its proposed biosimilar of Amgen's osteoporosis therapy Prolia/Xgeva with the FDA, saying it is "among the first" to fi

News

FDA approves GSK’s oral treatment of dialysis anaemia

The US Food and Drug Administration (FDA) has approved the

News

Lilly breaks new ground for BTK class with Jaypirca approval

Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla

News

EMA reviewing Novartis' Adakveo after phase 3 miss

The EMA's human medicines committee has started a review of Novartis' sickle cell disease (SCD) therapy Adakveo, shortly after the company reported that it failed to show efficacy in a phas

News

abstract shapes, bone structure, 3d render, bone

Ipsen's rare disease drug palovarotene knocked back in EU

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against

News

J&J copay lawsuit against drug benefit firm gets green light

Johnson & Johnson has been cleared to continue a lawsuit filed last year against drug benefit programme SaveOnSP, which claims it defrauded a payment assistance programme for patients o

Sandoz files biosimilar of Amgen osteoporosis drug in US

FDA approves GSK’s oral treatment of dialysis anaemia

Lilly breaks new ground for BTK class with Jaypirca approval

EMA reviewing Novartis' Adakveo after phase 3 miss

Ipsen's rare disease drug palovarotene knocked back in EU

J&J copay lawsuit against drug benefit firm gets green light

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks